Protagonist Therapeutics (PTGX) Competitors $49.87 -1.18 (-2.31%) Closing price 04:00 PM EasternExtended Trading$47.78 -2.10 (-4.20%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTGX vs. GMAB, RDY, QGEN, VTRS, ASND, MRNA, BBIO, BPMC, VRNA, and ROIVShould you be buying Protagonist Therapeutics stock or one of its competitors? The main competitors of Protagonist Therapeutics include Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Moderna (MRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Protagonist Therapeutics vs. Its Competitors Genmab A/S Dr. Reddy's Laboratories Qiagen Viatris Ascendis Pharma A/S Moderna BridgeBio Pharma Blueprint Medicines Verona Pharma PLC American Depositary Share Roivant Sciences Genmab A/S (NASDAQ:GMAB) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation. Which has more risk & volatility, GMAB or PTGX? Genmab A/S has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.26, indicating that its stock price is 126% more volatile than the S&P 500. Do insiders and institutionals have more ownership in GMAB or PTGX? 7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 4.9% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has better earnings & valuation, GMAB or PTGX? Genmab A/S has higher revenue and earnings than Protagonist Therapeutics. Genmab A/S is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenmab A/S$3.12B4.21$1.14B$1.7611.66Protagonist Therapeutics$434.43M7.11$275.19M$0.7566.49 Do analysts prefer GMAB or PTGX? Genmab A/S currently has a consensus price target of $37.60, suggesting a potential upside of 83.24%. Protagonist Therapeutics has a consensus price target of $66.10, suggesting a potential upside of 32.54%. Given Genmab A/S's higher possible upside, equities analysts clearly believe Genmab A/S is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genmab A/S 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.67Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media favor GMAB or PTGX? In the previous week, Protagonist Therapeutics had 1 more articles in the media than Genmab A/S. MarketBeat recorded 3 mentions for Protagonist Therapeutics and 2 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.58 beat Protagonist Therapeutics' score of 0.54 indicating that Genmab A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is GMAB or PTGX more profitable? Genmab A/S has a net margin of 35.11% compared to Protagonist Therapeutics' net margin of 27.04%. Genmab A/S's return on equity of 18.08% beat Protagonist Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Genmab A/S35.11% 18.08% 14.52% Protagonist Therapeutics 27.04%9.22%8.31% SummaryGenmab A/S and Protagonist Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTGX vs. The Competition Export to ExcelMetricProtagonist TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.16B$2.92B$5.53B$9.03BDividend YieldN/A2.44%5.24%4.07%P/E Ratio66.4920.3027.1920.03Price / Sales7.11251.54414.39108.98Price / Cash11.3041.7026.2128.59Price / Book4.407.397.925.55Net Income$275.19M-$55.04M$3.17B$248.49M7 Day Performance-9.77%3.01%2.18%5.37%1 Month Performance-8.29%-0.21%1.25%6.63%1 Year Performance47.89%4.48%33.90%21.20% Protagonist Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTGXProtagonist Therapeutics2.0636 of 5 stars$49.87-2.3%$66.10+32.5%+51.8%$3.16B$434.43M66.49120GMABGenmab A/S3.8379 of 5 stars$20.66+0.8%$37.60+82.0%-20.1%$13.15B$3.12B11.742,682RDYDr. Reddy's Laboratories2.6782 of 5 stars$15.03-0.3%$16.95+12.8%-3.4%$12.58B$3.81B22.7727,811QGENQiagen3.8493 of 5 stars$48.07+0.6%$49.40+2.8%+21.0%$10.62B$1.98B120.525,765Dividend AnnouncementVTRSViatris3.3418 of 5 stars$8.93-0.9%$10.40+16.5%-10.4%$10.57B$14.74B-2.8232,000ASNDAscendis Pharma A/S3.458 of 5 stars$172.60+0.2%$220.67+27.8%+28.2%$10.53B$393.54M-27.481,017MRNAModerna4.36 of 5 stars$27.59+1.6%$46.61+68.9%-74.2%$10.50B$3.24B-3.165,800BBIOBridgeBio Pharma4.673 of 5 stars$43.18-3.7%$58.85+36.3%+69.7%$8.52B$221.90M-12.23400High Trading VolumeBPMCBlueprint Medicines1.3655 of 5 stars$128.18+0.1%$128.06-0.1%+14.8%$8.27B$508.82M-51.89640Positive NewsVRNAVerona Pharma PLC American Depositary Share2.7573 of 5 stars$94.58+0.8%$101.10+6.9%+466.0%$7.99B$42.28M-47.2930Positive NewsROIVRoivant Sciences1.4901 of 5 stars$11.27-1.1%$17.50+55.3%+1.8%$7.74B$29.05M-45.08860 Related Companies and Tools Related Companies Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Qiagen Alternatives Viatris Alternatives Ascendis Pharma A/S Alternatives Moderna Alternatives BridgeBio Pharma Alternatives Blueprint Medicines Alternatives Verona Pharma PLC American Depositary Share Alternatives Roivant Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTGX) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
